PRIME Scheme: EMA Says Yes To Hookipa, Bluejay & 89bio But No To Six Others

 
• By Neena Brizmohun

Esepapogene zalarnarepvec, BJT-778 and pegozafermin are the latest investigational products that the European Medicines Agency said merited a place on its priority medicines scheme.

Holograms of capsule; charts and DNA helix on scientific backdrop. 3D illustration. Concept about pharmaceutical research and development; biochemical industry.
The PRIME scheme is designed to help companies optimize their drug development plans • Source: Shutterstock

More from R&D

More from Pink Sheet